Neoadjuvant or adjuvant chemotherapy for non-small-cell lung cancer: Does the timing matter?

Affiliations

¹ Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
² Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Electronic address: hqchen1@yahoo.com.

Free article

Editorial

Yang Zhang et al. J Thorac Cardiovasc Surg. 2019 Feb.

Free article

. 2019 Feb;157(2):756-757.

doi: 10.1016/j.jtcvs.2018.10.006. Epub 2018 Oct 12.

¹ Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
² Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Electronic address: hqchen1@yahoo.com.

No abstract available

Comment on

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS, Yan W, Zhou J, Tan KS, Montecalvo J, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Travis WD, Kris MG, Chaft JE, Jones DR. Brandt WS, et al. J Thorac Cardiovasc Surg. 2019 Feb;157(2):743-753.e3. doi: 10.1016/j.jtcvs.2018.09.098. Epub 2018 Oct 10. J Thorac Cardiovasc Surg. 2019. PMID: 30415902 Free PMC article.